An FDA-cleared, dual-modality therapeutic platform — designed for clinical professionals.
Watch how the world's first handheld cold plasma device is transforming clinical practices.
The MIRARI® Cold Plasma System operates on a dual-modality architecture, combining Radio frequency energy generator delivery in a single handheld device.
Targets superficial tissues with high water content, such as skin and soft tissue. In CAP mode, the device generates cold atmospheric plasma via Dielectric Barrier Discharge (DBD), delivering reactive oxygen and nitrogen species directly to the tissue surface.
Targets deeper, denser structures, such as tendons, ligaments, and joint capsules. In RES mode, 80 kHz monopolar radiofrequency energy is converted into controlled thermal energy as it encounters tissue resistance.
Targets superficial tissues with high water content, such as skin and soft tissue. In CAP mode, the device generates cold atmospheric plasma via Dielectric Barrier Discharge (DBD), delivering reactive oxygen and nitrogen species directly to the tissue surface.
Targets deeper, denser structures, such as tendons, ligaments, and joint capsules. In RES mode, 80 kHz monopolar radiofrequency energy is converted into controlled thermal energy as it encounters tissue resistance.
Rigorous compliance across biological safety, risk management, and device performance.
Developed over years of dedicated research, our granted U.S. patents represent the intellectual foundation of MIRARI® — protecting innovations that took decades of scientific expertise to achieve.
